Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12423890 | 0.80 | NCF1 (0.48) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL16877112 | 0.78 | — | — | |
| SCHEMBL24338296 | 0.77 | NCF1 (0.45) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL24337705 | 0.75 | NCF1 (0.43) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL102076 | 0.75 | NCF1 (0.52) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL27290779 | 0.74 | — | — | |
| SCHEMBL23570098 | 0.73 | NCF1 (0.50) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL26635857 | 0.72 | NCF1 (0.45) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL26635854 | 0.72 | NCF1 (0.45) | NCF1GNAI3GNAO1GNAI1HRH3 | |
| SCHEMBL26636987 | 0.72 | NCF1 (0.45) | NCF1GNAI3GNAO1GNAI1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011033094-A1 | SCHEDULE OF ADMINISTRATION OF BENZAZOLE DERIVATIVES IN THE TREATMENT OF LEUKEMIAS | 4SC AG (DE) | 2011-03-24 | — | — | WO | disclosed |
| EP-1948651-A1 | THIAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20070149523-A1 | Thiazole Analogues and Uses Thereof | 4SC AG (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007054357-A1 | THIAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1785420-A1 | Thiazole analogues and uses thereof | 4SC AG (DE) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149523-A1 | Thiazole Analogues and Uses Thereof | NR3C2, SLC26A4, CLIC4 | NCF1 2220/4885GNAI3 2755/4885GNAO1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.